Volitionrx Limited (VNRX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock
Get Alerts VNRX Hot Sheet
Join SI Premium – FREE
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced the pricing of its underwritten public offering of 3,809,524 shares of its common stock (the "Offering") for gross proceeds of approximately $20 million, before deducting the underwriting commissions and other estimated offering expenses payable by Volition. All of the shares to be sold in the Offering will be sold by Volition, subject to customary closing conditions. The Offering is expected to close on or about February 12, 2021, subject to customary closing conditions. In addition, Volition has granted the underwriter for the Offering a 30-day option to purchase up to an additional 571,428 shares of its common stock.
Cantor Fitzgerald & Co. is acting as the sole book running manager of the Offering.
The underwriter may offer the shares from time to time for sale in one or more transactions on the NYSE American market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. On February 9, 2021, the last sale price of the shares as reported on the NYSE American was $6.27 per share.
Volition intends to use the net proceeds of the Offering for general corporate purposes, which may include continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- INmune Bio (INMB) Prices 986K Share Offering at $9.84/sh
- Centessa Pharmaceuticals (CNTA) Announces $100 Million Proposed Public Offering of American Depositary Shares
- Immunome Inc. (IMNM) Appoints Sandra M. Swain to its Board
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsRelated Entities
Cantor Fitzgerald, S3Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!